⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMT News
Sagimet Biosciences Inc. Series A Common Stock
Form 8-K
sec.gov
SGMT
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com
SGMT
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
SGMT
Form 8-K
sec.gov
SGMT
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
globenewswire.com
SGMT
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
globenewswire.com
SGMT
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
globenewswire.com
SGMT
Form 8-K
sec.gov
SGMT
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
globenewswire.com
SGMT
Form 8-K
sec.gov
SGMT